
Collegium Pharmaceutical (COLL) Stock Forecast & Price Target
Collegium Pharmaceutical (COLL) Analyst Ratings
Bulls say
Collegium Pharmaceutical Inc. demonstrates a robust financial outlook, driven by significant growth in its product Jornay, which achieved $42 million in revenue, reflecting a 19% year-over-year increase and surpassing market expectations. The company is implementing an expanded sales force, increasing from 55 to 180 representatives, which is projected to enhance education and awareness among healthcare providers and patients, further positioning Jornay for sustained market share growth. With a consistent trend of increasing prescriptions and a solid foundation in its abuse-deterrent technology, Collegium is well-positioned to capitalize on the safer opioid theme, reinforcing its potential for continued top-line performance through 2026 and beyond.
Bears say
Collegium Pharmaceutical Inc. faces a negative outlook due to several financial risks, primarily stemming from lower projected sales for key products such as Xtampza ER and Belbuca, with 2026 guidance indicating a decline in pain portfolio sales to approximately $620 million compared to $632 million in 2025. Additionally, there are significant concerns regarding earlier generic competition for these products and the potential impact on net profits from third-party generics, which could further dampen revenue expectations. Execution risks linked to commercialization and the reliability of third-party suppliers also pose serious challenges that could affect the overall profitability of Collegium’s offerings.
This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction
Start investing in Collegium Pharmaceutical (COLL)
Order type
Buy in
Order amount
Est. shares
0 shares